EA201891664A1 - Составы/композиции, содержащие ингибитор btk - Google Patents

Составы/композиции, содержащие ингибитор btk

Info

Publication number
EA201891664A1
EA201891664A1 EA201891664A EA201891664A EA201891664A1 EA 201891664 A1 EA201891664 A1 EA 201891664A1 EA 201891664 A EA201891664 A EA 201891664A EA 201891664 A EA201891664 A EA 201891664A EA 201891664 A1 EA201891664 A1 EA 201891664A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
btk inhibitor
containing btk
compositions containing
methods
Prior art date
Application number
EA201891664A
Other languages
English (en)
Inventor
Маниш Кумар Гупта
Парикшит Рамешрао Кулкарни
Бинурадж Кришнан Наир
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201891664A1 publication Critical patent/EA201891664A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Раскрыты составы/композиции, содержащие ингибитор BTK, в частности ибрутиниб (I), а также способы получения таких составов/композиций и способы лечения заболевания или состояния, которые предусматривают применение таких составов/композиций.
EA201891664A 2016-01-19 2017-01-18 Составы/композиции, содержащие ингибитор btk EA201891664A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621001987 2016-01-19
PCT/EP2017/050964 WO2017125424A1 (en) 2016-01-19 2017-01-18 Formulations/compositions comprising a btk inhibitor

Publications (1)

Publication Number Publication Date
EA201891664A1 true EA201891664A1 (ru) 2019-02-28

Family

ID=57851068

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891664A EA201891664A1 (ru) 2016-01-19 2017-01-18 Составы/композиции, содержащие ингибитор btk

Country Status (15)

Country Link
US (3) US20190290650A1 (ru)
EP (1) EP3405178A1 (ru)
JP (2) JP7336195B2 (ru)
KR (1) KR20180102150A (ru)
CN (2) CN114681462A (ru)
AR (1) AR107392A1 (ru)
AU (1) AU2017208473B2 (ru)
BR (1) BR112018014540B1 (ru)
CA (1) CA3008576A1 (ru)
EA (1) EA201891664A1 (ru)
HK (2) HK1259441A1 (ru)
MA (1) MA43650A (ru)
MX (2) MX2018008772A (ru)
TW (1) TWI794153B (ru)
WO (1) WO2017125424A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702548A (en) 2012-06-04 2015-11-27 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
SG10202102078VA (en) * 2015-03-03 2021-04-29 Pharmacyclics Llc Pharmaceutical formulations of a bruton’s tyrosine kinase inhibitor
US11576917B2 (en) 2018-01-20 2023-02-14 Natco Pharma Limited Pharmaceutical compositions comprising Ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
CN112292117A (zh) 2018-06-15 2021-01-29 詹森药业有限公司 包含依鲁替尼的配制品/组合物
US10688050B1 (en) * 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
DK0580860T4 (da) 1991-04-16 2005-03-21 Nippon Shinyaku Co Ltd Fremgangsmåde til fremstilling af en fast dispersion
JPH07501073A (ja) 1991-11-22 1995-02-02 プロクター、エンド、ギャンブル、ファーマス−ティカルズ、インコーポレーテッド リゼドロネート遅延放出組成物
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1664762A4 (en) 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHODS OF IDENTIFICATION, DIAGNOSIS AND PREDICTION FOR LYMPHOMES SURVIVAL
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
EA032463B1 (ru) * 2011-10-19 2019-05-31 Фармасайкликс Элэлси Применение ингибиторов тирозинкиназы брутона (втк)
NZ702548A (en) * 2012-06-04 2015-11-27 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
BR112015021995A2 (pt) * 2013-03-14 2017-07-18 Pharmacyclics Llc combinações de inibidores de tirosina quinase de bruton e inibidores de cyp3a4
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物

Also Published As

Publication number Publication date
CA3008576A1 (en) 2017-07-27
MA43650A (fr) 2018-11-28
HK1259441A1 (zh) 2019-11-29
MX2022006817A (es) 2022-07-11
JP7336195B2 (ja) 2023-08-31
BR112018014540B1 (pt) 2024-02-27
JP2022105006A (ja) 2022-07-12
HK1259433A1 (zh) 2019-11-29
US20210169888A1 (en) 2021-06-10
CN114681462A (zh) 2022-07-01
KR20180102150A (ko) 2018-09-14
CN108472258A (zh) 2018-08-31
AR107392A1 (es) 2018-04-25
US20190290650A1 (en) 2019-09-26
TW201737918A (zh) 2017-11-01
US20230364090A1 (en) 2023-11-16
EP3405178A1 (en) 2018-11-28
BR112018014540A2 (pt) 2018-12-11
AU2017208473B2 (en) 2022-04-21
WO2017125424A1 (en) 2017-07-27
MX2018008772A (es) 2018-11-09
TWI794153B (zh) 2023-03-01
AU2017208473A1 (en) 2018-07-12
JP2019506450A (ja) 2019-03-07

Similar Documents

Publication Publication Date Title
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201992209A1 (ru) Модифицированные циклические динуклеотидные соединения
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201792529A1 (ru) Ингибиторы тирозинкиназы
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790317A1 (ru) Ингибиторы smyd
EA201591743A1 (ru) СТИМУЛЯТОРЫ sGC
EA201790413A1 (ru) Антитела против tigit
EA201790376A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201692513A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201791095A1 (ru) Способ лечения рака
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA202090183A1 (ru) Композиции, способы и получение дейтерированного домперидона
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
EA201891342A1 (ru) Изоиндольные соединения
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
EA201892287A1 (ru) Фармацевтические комбинации для лечения рака
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы